Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.54 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11844469 | 0.91 | CYP1A2 (0.65) | CYP1A2CYP2C9CYP2C19HTTALDH1A1 | |
| 1,2-Diisopentoxybenzene SCHEMBL2843498 | 0.86 | HTT (0.62) | HTTALDH1A1TLR8MCHR1TDP1 | |
| SCHEMBL21104793 | 0.85 | CYP1A2 (0.58) | CYP1A2CYP2C9CYP2C19HTTALDH1A1 | |
| SCHEMBL21104226 | 0.85 | CYP1A2 (0.58) | CYP1A2CYP2C9CYP2C19HTTALDH1A1 | |
| SCHEMBL20021062 | 0.84 | CYP1A2 (0.61) | CYP1A2CYP2C9CYP2C19HTTALDH1A1 | |
| SCHEMBL294796 | 0.82 | MCHR1 (0.52) | CYP1A2CYP2C9CYP2C19HTTALDH1A1 | |
| SCHEMBL29708563 | 0.81 | CYP1A2 (0.72) | CYP1A2CYP2C9CYP2C19HTTALDH1A1 | |
| SCHEMBL864648 | 0.81 | CYP1A2 (0.72) | CYP1A2CYP2C9CYP2C19HTTALDH1A1 | |
| SCHEMBL110055 | 0.80 | ALDH1A1 (0.61) | CYP1A2CYP2C9CYP2C19ALDH1A1TLR8 | |
| SCHEMBL18217408 | 0.79 | CYP1A2 (0.59) | CYP1A2CYP2C9CYP2C19HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1063987-A4 | DIETARY CONTROL OF ARACHIDONIC ACID METABOLISM | UNIV WAKE FOREST (US) | 2005-01-12 | — | — | EP | claimed |
| WO-2003063793-A2 | FATTY ACID-CONTAINING COMPOSITIONS AND METHODS FOR THE TREATMENT OF CYTOKINE MEDIATED DISORDERS | PILOT THERAPEUTICS, INC. (US) | 2003-08-07 | — | — | WO | claimed |
| EP-1063987-A1 | DIETARY CONTROL OF ARACHIDONIC ACID METABOLISM | WAKE FOREST UNIVERSITY (US) | 2001-01-03 | — | — | EP | claimed |
| WO-1999042101-A1 | DIETARY CONTROL OF ARACHIDONIC ACID METABOLISM | WAKE FOREST UNIVERSITY (US) | 1999-08-26 | — | — | WO | claimed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9802937-B2 | Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-10-31 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-9499535-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2016-11-22 | — | — | US | disclosed |
| EP-2699572-B1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2016-08-10 | — | — | EP | disclosed |
| EP-2699579-B1 | PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| WO-2014060113-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| WO-2014060112-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| US-20120329785-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20120329780-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
| EP-2426135-A1 | UREA DERIVATIVE HAVING PI3K INHIBITORY ACTIVITY | Shionogi&Co., Ltd. (JP) | 2012-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | CYP1A2 3832/4885CYP2C9 3823/4885CYP2C19 2941/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | CYP1A2 3832/4885CYP2C9 3823/4885CYP2C19 2941/4885 |
| US-20120329780-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK | CYP1A2 3832/4885CYP2C9 3823/4885CYP2C19 2941/4885 |
| US-20120329785-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK3 | CYP1A2 4700/4885CYP2C9 4631/4885CYP2C19 4548/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | CYP1A2 3709/4885CYP2C9 3714/4885CYP2C19 2888/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | CYP1A2 3709/4885CYP2C9 3714/4885CYP2C19 2888/4885 |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | MTOR, STAT3, SLC14A1 | CYP1A2 4604/4885CYP2C9 3873/4885CYP2C19 3637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.